These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17936869)

  • 1. Relative concordance of human immunodeficiency virus oligomeric and monomeric envelope in CCR5 coreceptor usage.
    Teeravechyan S; Suphaphiphat P; Essex M; Lee TH
    Virology; 2008 Jan; 370(2):443-50. PubMed ID: 17936869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
    Platt EJ; Shea DM; Rose PP; Kabat D
    J Virol; 2005 Apr; 79(7):4357-68. PubMed ID: 15767436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
    Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    Reeves JD; Miamidian JL; Biscone MJ; Lee FH; Ahmad N; Pierson TC; Doms RW
    J Virol; 2004 May; 78(10):5476-85. PubMed ID: 15113926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1.
    Olivieri K; Scoggins RM; Bor YC; Matthews A; Mark D; Taylor JR; Chernauskas D; Hammarskjöld ML; Rekosh D; Camerini D
    Virology; 2007 Feb; 358(1):23-38. PubMed ID: 16999983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional impact of HIV coreceptor-binding site mutations.
    Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD
    Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
    Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
    Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals.
    Braun P; Wiesmann F
    Eur J Med Res; 2007 Oct; 12(9):463-72. PubMed ID: 17933728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.
    Lobritz MA; Marozsan AJ; Troyer RM; Arts EJ
    J Virol; 2007 Aug; 81(15):8258-69. PubMed ID: 17522224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
    Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
    J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Originality of entry inhibitors].
    Izopet J
    Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H1-4. PubMed ID: 19837343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.